Tyche Wealth Partners LLC Takes Position in Humana Inc. (NYSE:HUM)

Tyche Wealth Partners LLC bought a new stake in Humana Inc. (NYSE:HUM) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 592 shares of the insurance provider’s stock, valued at approximately $271,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in HUM. Cibc World Market Inc. raised its position in shares of Humana by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock valued at $2,484,000 after buying an additional 217 shares in the last quarter. Blair William & Co. IL increased its position in Humana by 0.6% during the 1st quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock worth $2,463,000 after purchasing an additional 32 shares in the last quarter. Cetera Investment Advisers increased its position in Humana by 0.5% during the 1st quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock worth $2,135,000 after purchasing an additional 26 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in Humana by 19.0% during the 1st quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock worth $268,000 after purchasing an additional 98 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. increased its position in Humana by 25.0% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock worth $12,971,000 after purchasing an additional 5,964 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HUM has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft cut shares of Humana from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $595.00 to $360.00 in a research report on Thursday, January 25th. Barclays lowered their price objective on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. Truist Financial reissued a “hold” rating and set a $550.00 target price on shares of Humana in a report on Friday, January 19th. Oppenheimer reissued an “outperform” rating and set a $630.00 target price on shares of Humana in a report on Wednesday, January 17th. Finally, Wells Fargo & Company reduced their target price on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a report on Monday, April 8th. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $465.42.

Insider Buying and Selling

In related news, Director Jorge S. Mesquita bought 545 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the purchase, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.32% of the stock is owned by insiders.

Humana Trading Up 1.9 %

NYSE:HUM opened at $323.46 on Thursday. The firm’s fifty day moving average is $344.41 and its 200-day moving average is $425.71. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. Humana Inc. has a 52 week low of $299.23 and a 52 week high of $541.21. The firm has a market cap of $39.03 billion, a P/E ratio of 16.32, a P/E/G ratio of 1.86 and a beta of 0.45.

Humana (NYSE:HUM) last posted its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The firm had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. During the same period in the prior year, the company posted $1.62 earnings per share. The company’s revenue for the quarter was up 17.9% compared to the same quarter last year. Equities analysts expect that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.09%. Humana’s dividend payout ratio is presently 17.86%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.